AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
170 hedge funds and large institutions have $803M invested in AMAG Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 53 increasing their positions, 62 reducing their positions, and 28 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
53% more capital invested
Capital invested by funds: $526M → $803M (+$276M)
4% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 28
0.4% more ownership
Funds ownership: 112.26% → 112.66% (+0.4%)
0% more funds holding
Funds holding: 170 → 170 (0)
15% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 62
63% less call options, than puts
Call options by funds: $5.54M | Put options by funds: $14.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$32.2M |
| 2 |
Renaissance Technologies
New York
|
+$11.7M |
| 3 |
BC
Broadfin Capital
New York
|
+$10.1M |
| 4 |
CEI
Clark Estates Inc
New York
|
+$4.14M |
| 5 |
JP Morgan Chase
New York
|
+$4.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
-$14.8M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$7.55M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$7.05M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$6.17M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$5.33M |
AMAG Hedge Fund Activity: Q1 2018 in Review
170 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q1 2018, worth a combined $803M — up 53% from $526M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new AMAG positions and 28 closed out — a net gain of 1 holder — while 53 added to existing stakes and 62 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $32.2M. The largest seller was LSV Asset Management, exiting entirely with an estimated $14.8M sold.
- 170 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $803M of AMAG Pharmaceuticals stock for Q1 2018, up 53% quarter-over-quarter.
- 29 funds opened new AMAG Pharmaceuticals positions in Q1 2018 and 28 closed out, a net change of +1 holder.
- The largest AMAG Pharmaceuticals buyer in Q1 2018 was Armistice Capital, an estimated $32.2M added.
- The largest AMAG Pharmaceuticals seller in Q1 2018 was LSV Asset Management, an estimated $14.8M sold.
Based on aggregated 13F filings for Q1 2018.